Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma

4 May 2021

Abstract excerpt

INTRODUCTION: gene. Inappropriate hypoxia-inducible factor (HIF)-mediated transcription of proangiogenic and metabolic genes leads to the development of tumors and cysts in multiple organs. Surgery is a standard treatment for localized tumors with a risk of metastasis or organ dysfunction. Repeated surgeries cause substantial morbidity and have a major impact on quality of life. There is an urgent need to develop...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal and Paraganglionic Tumors
Share to Autophagy in Disease and Therapy
Share to Cancer, Hypoxia, and Metabolism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33945366
DOI: 10.1080/13543784.2021.1925248

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinomaPMID 33945366Read ↗

Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted TherapiesSemantic proximity Read ↗

Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.Semantic proximity Read ↗

Treatment of kidney cancerSemantic proximity Read ↗

Renal Cell Carcinoma in von Hippel–Lindau Disease—From Tumor Genetics to Novel Therapeutic StrategiesSemantic proximity Read ↗

State of the science: an update on renal cell carcinoma.Semantic proximity Read ↗

Molecular basis for the treatment of renal cell carcinoma.Semantic proximity Read ↗

Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective.Semantic proximity Read ↗

Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor HypoxiaSemantic proximity Read ↗

Development of drugs targeting hypoxia-inducible factor against tumor cells with VHL mutation: Story of 127 years.Semantic proximity Read ↗

2'-hydroxyflavanone inhibits proliferation, tumor vascularization and promotes normal differentiation in VHL-mutant renal cell carcinoma.Semantic proximity Read ↗

Molecular biology of renal cell carcinoma.Semantic proximity Read ↗

Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.